Respiratory Medicine and Research最新文献_第6页

Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice 不可切除的III期非小细胞肺癌的现实世界管理：杜伐单抗巩固治疗在法国临床实践中的影响。

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-10-09 DOI: 10.1016/j.resmer.2025.101216

Christos Chouaid , Philippe Giraud , Marie Wislez , Eric Pichon , Alma Stancu , Didier Debieuvre , Nicolas Girard , Maurice Pérol , Xavier Quantin , Sabine Ano , Françoise Grela , Nina Goyard , Mathieu Fore , Fanny Magne , Vanessa Pante , Lydie Lemonnier-Videau , Lionel Falchero

Background

Durvalumab consolidation therapy has improved survival after chemoradiotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Our three-cohort study from France described the real-world effectiveness and safety of durvalumab in unresectable stage III NSCLC.

Methods

We analysed three durvalumab-treated cohorts: the French PACIFIC-R cohort (n=342), the prospective KBP-2020-CPHG cohort (n=178), and the ESME lung cancer registry (n=604). Progression-free survival (PFS) and overall survival (OS) were assessed from start of durvalumab (in French PACIFIC-R and KBP-2020-CPHG) or end of radiotherapy (in ESME). Safety data were available for the French PACIFIC-R cohort.

Results

In French PACIFIC-R, at a median follow-up of 39.4 months, median PFS was 22.6 months and median OS was not reached. At 3 years, OS was 61.1%. Median PFS was 13.0 months in patients with programmed death-ligand 1 (PD-L1) expression <1% versus 25.3 months in those with PD-L1 ≥1%. Pneumonitis/interstitial lung disease occurred in 17.8% of patients, with no fatal events. In KBP-2020-CPHG, median PFS was 18.5 months and median OS was not reached. Three-year OS was 55.0%. Patients with PD-L1 expression >50% had a 3-year OS rate of 68.4% compared to 48.5% in those with PD-L1 expression 1%–50%. In ESME, median PFS was 21.2 months and median OS was 50.7 months. The 3-year and 5-year OS rates were 61.3% and 46.9%, respectively. Among 308 patients with N2 stage disease, median PFS was 25.6 months and median OS was 56.4 months from NSCLC diagnosis.

Conclusions

Real-world evidence from three large French cohorts underscores the sustained effectiveness and manageable safety profile of durvalumab consolidation therapy after chemoradiotherapy in unresectable stage III NSCLC.

背景：Durvalumab巩固治疗提高了晚期非小细胞肺癌（NSCLC）患者放化疗后的生存率。我们来自法国的三队列研究描述了durvalumab在不可切除的III期NSCLC中的实际有效性和安全性。方法：我们分析了三个durvalumab治疗的队列：法国PACIFIC-R队列（n=342），前瞻性KBP-2020-CPHG队列（n=178）和ESME肺癌登记处（n=604）。从杜伐单抗开始（法国PACIFIC-R和KBP-2020-CPHG）或放疗结束（ESME）开始评估无进展生存期（PFS）和总生存期（OS）。法国PACIFIC-R队列的安全性数据可用。结果：在法国PACIFIC-R中，中位随访39.4个月，中位PFS为22.6个月，中位OS未达到。3年时，OS为61.1%。程序性死亡-配体1 （PD-L1）表达50%的患者中位PFS为13.0个月，3年OS率为68.4%，而PD-L1表达1%-50%的患者中位PFS为48.5%。ESME患者中位PFS为21.2个月，中位OS为50.7个月。3年和5年的总生存率分别为61.3%和46.9%。在308例N2期疾病患者中，从NSCLC诊断开始，中位PFS为25.6个月，中位OS为56.4个月。结论：来自三个大型法国队列的真实证据强调了在不可切除的III期NSCLC放化疗后durvalumab巩固治疗的持续有效性和可管理的安全性。

{"title":"Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice","authors":"Christos Chouaid , Philippe Giraud , Marie Wislez , Eric Pichon , Alma Stancu , Didier Debieuvre , Nicolas Girard , Maurice Pérol , Xavier Quantin , Sabine Ano , Françoise Grela , Nina Goyard , Mathieu Fore , Fanny Magne , Vanessa Pante , Lydie Lemonnier-Videau , Lionel Falchero","doi":"10.1016/j.resmer.2025.101216","DOIUrl":"10.1016/j.resmer.2025.101216","url":null,"abstract":"<div><h3>Background</h3><div>Durvalumab consolidation therapy has improved survival after chemoradiotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Our three-cohort study from France described the real-world effectiveness and safety of durvalumab in unresectable stage III NSCLC.</div></div><div><h3>Methods</h3><div>We analysed three durvalumab-treated cohorts: the French PACIFIC-R cohort (n=342), the prospective KBP-2020-CPHG cohort (n=178), and the ESME lung cancer registry (n=604). Progression-free survival (PFS) and overall survival (OS) were assessed from start of durvalumab (in French PACIFIC-R and KBP-2020-CPHG) or end of radiotherapy (in ESME). Safety data were available for the French PACIFIC-R cohort.</div></div><div><h3>Results</h3><div>In French PACIFIC-R, at a median follow-up of 39.4 months, median PFS was 22.6 months and median OS was not reached. At 3 years, OS was 61.1%. Median PFS was 13.0 months in patients with programmed death-ligand 1 (PD-L1) expression <1% versus 25.3 months in those with PD-L1 ≥1%. Pneumonitis/interstitial lung disease occurred in 17.8% of patients, with no fatal events. In KBP-2020-CPHG, median PFS was 18.5 months and median OS was not reached. Three-year OS was 55.0%. Patients with PD-L1 expression >50% had a 3-year OS rate of 68.4% compared to 48.5% in those with PD-L1 expression 1%–50%. In ESME, median PFS was 21.2 months and median OS was 50.7 months. The 3-year and 5-year OS rates were 61.3% and 46.9%, respectively. Among 308 patients with N2 stage disease, median PFS was 25.6 months and median OS was 56.4 months from NSCLC diagnosis.</div></div><div><h3>Conclusions</h3><div>Real-world evidence from three large French cohorts underscores the sustained effectiveness and manageable safety profile of durvalumab consolidation therapy after chemoradiotherapy in unresectable stage III NSCLC.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101216"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145402320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endobronchial valve (EBV) insertion for severe emphysema does not improve skeletal muscle mass or function: A pilot study on 19 patients 支气管内瓣膜（EBV）插入治疗严重肺气肿不能改善骨骼肌质量或功能：一项19例患者的初步研究

IF 2.2 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-05-22 DOI: 10.1016/j.resmer.2025.101178

Julia Rubenstein , Ilyès Benlala , Emilie Mesa , Anne-Claire Toublanc , Marina Gueçamburu , Arnaud Maurac , Claire Bon , Charlotte Vergnenegre , Léo Grassion , Geoffroy Moucheboeuf , Patrick Dehail , Gaël Dournes , Maéva Zysman , Pauline Henrot

Endobronchial valve (EBV) insertion for severe emphysema allows to reduce hyperinflation and alleviates respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD). However, few studies investigate its effect on extra-pulmonary manifestations. We sought to assess the effect of EBV insertion on skeletal muscle mass and function, as well as determine if skeletal muscle parameters could represent a prognostic factor for response to EBV insertion.

We conducted a monocentric prospective pilot study including 19 patients. Exhaustive evaluation of lung & skeletal muscle parameters was performed at baseline and 3 and 6 months after EBV insertion. Our primary aim was to assess the 6-month change in skeletal muscle parameters i.e. assessment of body composition with bioimpedance analysis (appendicular skeletal muscle mass index, fat mass, phase angle), evaluation of thoracic muscles (pectoralis, erector spinal, 5th intercostalis, psoas) surfaces and densities on CT-scans, and of upper limb force with handgrip test.

EBV insertion led to a significant improvement of lung function after 3 months and persisting at 6 months. In contrast, no significant improvement was observed in skeletal muscle parameters. In addition, no muscle parameter nor sarcopenic status was found to predict response to EBV insertion.

These results suggest that EBV insertion is not associated with strong systemic effects in our study, as well as emphasize the need to find bottom-up drug strategies for COPD-associated sarcopenia.

支气管内瓣膜（EBV）插入治疗严重肺气肿可以减少慢性阻塞性肺疾病（COPD）患者的恶性膨胀并缓解呼吸道症状。然而，很少有研究探讨其对肺外表现的影响。我们试图评估EBV插入对骨骼肌质量和功能的影响，并确定骨骼肌参数是否可以代表EBV插入反应的预后因素。我们进行了一项包括19名患者的单中心前瞻性先导研究。肺的详尽评估；骨骼肌参数在基线和EBV植入后3个月和6个月进行。我们的主要目的是评估6个月骨骼肌参数的变化，即通过生物阻抗分析评估身体成分（阑尾骨骼肌质量指数、脂肪质量、相位角），通过ct扫描评估胸肌（胸肌、竖脊肌、第五肋间肌、腰肌）的表面和密度，以及通过握力测试评估上肢力量。EBV植入3个月后肺功能显著改善，并持续到6个月。相比之下，骨骼肌参数没有明显改善。此外，没有发现肌肉参数或肌肉减少状态可以预测EBV插入的反应。这些结果表明，在我们的研究中，EBV插入与强烈的全身效应无关，并强调需要寻找自下而上的药物策略来治疗copd相关的肌肉减少症。

{"title":"Endobronchial valve (EBV) insertion for severe emphysema does not improve skeletal muscle mass or function: A pilot study on 19 patients","authors":"Julia Rubenstein , Ilyès Benlala , Emilie Mesa , Anne-Claire Toublanc , Marina Gueçamburu , Arnaud Maurac , Claire Bon , Charlotte Vergnenegre , Léo Grassion , Geoffroy Moucheboeuf , Patrick Dehail , Gaël Dournes , Maéva Zysman , Pauline Henrot","doi":"10.1016/j.resmer.2025.101178","DOIUrl":"10.1016/j.resmer.2025.101178","url":null,"abstract":"<div><div>Endobronchial valve (EBV) insertion for severe emphysema allows to reduce hyperinflation and alleviates respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD). However, few studies investigate its effect on extra-pulmonary manifestations. We sought to assess the effect of EBV insertion on skeletal muscle mass and function, as well as determine if skeletal muscle parameters could represent a prognostic factor for response to EBV insertion.</div><div>We conducted a monocentric prospective pilot study including 19 patients. Exhaustive evaluation of lung & skeletal muscle parameters was performed at baseline and 3 and 6 months after EBV insertion. Our primary aim was to assess the 6-month change in skeletal muscle parameters i.e. assessment of body composition with bioimpedance analysis (appendicular skeletal muscle mass index, fat mass, phase angle), evaluation of thoracic muscles (pectoralis, erector spinal, 5th intercostalis, psoas) surfaces and densities on CT-scans, and of upper limb force with handgrip test.</div><div>EBV insertion led to a significant improvement of lung function after 3 months and persisting at 6 months. In contrast, no significant improvement was observed in skeletal muscle parameters. In addition, no muscle parameter nor sarcopenic status was found to predict response to EBV insertion.</div><div>These results suggest that EBV insertion is not associated with strong systemic effects in our study, as well as emphasize the need to find bottom-up drug strategies for COPD-associated sarcopenia.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101178"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological disparities in pulmonary sarcoidosis between public and private healthcare sectors in haute-Garonne department (France). 法国上加隆省公立和私立医疗保健部门肺结节病的流行病学差异。

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-05-21 DOI: 10.1016/j.resmer.2025.101177

Nicolas Le Divenah, Grégoire Prévot, Aurélie Le Borgne, Florence Lintz, Gisèle Mourin, Pierre-Jean Esquerre, Jean-Christophe Aubry, William Heurtaux, Laura Petrov, Emilie Bousquet, Myriam Delaunay, Guillaume Faviez, Meritxell Pasto-Catusse, Jean-Marc Vernejoux, Marie-Christine Pujazon, Romain Barthes, Alain Didier, Julien Mazières, Nicolas Guibert, Thomas Villeneuve

Introduction: Sarcoidosis is a multisystem granulomatous disorder that affects mediastinal and pulmonary structures in nearly 90% of cases. Given the high prevalence of respiratory involvement, pulmonologists are crucial in managing the disease, from diagnosis through to follow-up. In France, epidemiological data on sarcoidosis are limited, despite notable regional and international variations in the incidence and prevalence of the disease.

Materials and methods: The SARCOPIDEMIO study is a prospective, multicenter observational study designed to estimate the incidence and prevalence of pulmonary sarcoidosis in the Haute-Garonne department (France). A total of 55 pulmonologists, representing both hospital-based and private practices, were invited to participate.

Results: A total of 172 patients were included in the analysis. The minimal and estimated prevalence rates were determined to be 14.8 to 29.6 cases per 100,000 inhabitants, respectively. The incidence rate was 3.6 new cases per 100,000 inhabitants per year. Histological confirmation of granuloma was obtained in approximately 78% of the patients. Half of the patients received corticosteroid therapy, while one-quarter were treated with second-line immunosuppressive agents. The distribution of patients between public and private sectors was relatively balanced; however, multisystemic clinical presentations and the need for treatment were more frequently observed in hospital settings.

Conclusion: The epidemiological data on pulmonary sarcoidosis from the Haute-Garonne department are relatively with those previously reported in France. Although sarcoidosis is a rare disease, its management is shared by all pulmonologists in our region.

结节病是一种多系统肉芽肿性疾病，近90%的病例影响纵隔和肺部结构。鉴于呼吸系统受累的高患病率，从诊断到随访，肺科医生在控制疾病方面至关重要。在法国，关于结节病的流行病学数据有限，尽管该疾病的发病率和流行率在区域和国际上存在显著差异。材料和方法：SARCOPIDEMIO研究是一项前瞻性、多中心观察性研究，旨在估计上加隆省（法国）肺结节病的发病率和患病率。共有55名代表医院和私人诊所的肺科医生应邀参加。结果：共纳入172例患者。确定的最低流行率和估计流行率分别为每10万居民14.8至29.6例。发病率为每年每10万居民3.6例新发病例。组织学上证实肉芽肿的患者约占78%。一半的患者接受皮质类固醇治疗，而四分之一的患者接受二线免疫抑制剂治疗。病人在公营和私营部门之间的分布相对平衡；然而，多系统临床表现和治疗需求在医院环境中更常见。结论：上加隆省肺结节病的流行病学资料与法国既往报道的流行病学资料比较一致。虽然结节病是一种罕见的疾病，但它的管理是我们地区所有肺科医生共同的。

{"title":"Epidemiological disparities in pulmonary sarcoidosis between public and private healthcare sectors in haute-Garonne department (France).","authors":"Nicolas Le Divenah, Grégoire Prévot, Aurélie Le Borgne, Florence Lintz, Gisèle Mourin, Pierre-Jean Esquerre, Jean-Christophe Aubry, William Heurtaux, Laura Petrov, Emilie Bousquet, Myriam Delaunay, Guillaume Faviez, Meritxell Pasto-Catusse, Jean-Marc Vernejoux, Marie-Christine Pujazon, Romain Barthes, Alain Didier, Julien Mazières, Nicolas Guibert, Thomas Villeneuve","doi":"10.1016/j.resmer.2025.101177","DOIUrl":"10.1016/j.resmer.2025.101177","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcoidosis is a multisystem granulomatous disorder that affects mediastinal and pulmonary structures in nearly 90% of cases. Given the high prevalence of respiratory involvement, pulmonologists are crucial in managing the disease, from diagnosis through to follow-up. In France, epidemiological data on sarcoidosis are limited, despite notable regional and international variations in the incidence and prevalence of the disease.</p><p><strong>Materials and methods: </strong>The SARCOPIDEMIO study is a prospective, multicenter observational study designed to estimate the incidence and prevalence of pulmonary sarcoidosis in the Haute-Garonne department (France). A total of 55 pulmonologists, representing both hospital-based and private practices, were invited to participate.</p><p><strong>Results: </strong>A total of 172 patients were included in the analysis. The minimal and estimated prevalence rates were determined to be 14.8 to 29.6 cases per 100,000 inhabitants, respectively. The incidence rate was 3.6 new cases per 100,000 inhabitants per year. Histological confirmation of granuloma was obtained in approximately 78% of the patients. Half of the patients received corticosteroid therapy, while one-quarter were treated with second-line immunosuppressive agents. The distribution of patients between public and private sectors was relatively balanced; however, multisystemic clinical presentations and the need for treatment were more frequently observed in hospital settings.</p><p><strong>Conclusion: </strong>The epidemiological data on pulmonary sarcoidosis from the Haute-Garonne department are relatively with those previously reported in France. Although sarcoidosis is a rare disease, its management is shared by all pulmonologists in our region.</p>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"101177"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Severe respiratory syncytial virus infection in older adults – burden, clinical outcomes and implications for care 老年人严重呼吸道合胞病毒感染——负担、临床结局和护理意义

IF 2.2 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-05-06 DOI: 10.1016/j.resmer.2025.101173

Daniel Guimarães de Oliveira , Ana Grande , Francisco Belchior , Rafaela Costa , Rita Francisco , Natália Oliveira , Maria Calle

Background

Respiratory syncytial virus (RSV) infection in adults remains under-researched. Increased testing is revealing an emerging picture of severe outcomes within the most prevalent lower respiratory tract infections. Understanding risk factors is increasingly important, especially in light of the recent approval of prophylactic vaccination.

Methods

Retrospective evaluation of all real-time polymerase chain reaction-positive RSV cases detected at our institution over three consecutive infection seasons from 2021 to 2024 in adults aged 60 years and older. Subsequent assessment of patients with severe infection requiring hospitalization.

Results

A total of 574 individuals were included, 57 % of whom were female, with a median age of 81,1 years (IQR 74–87 years). The peak number of cases occurred between September and March. We found a hospitalization rate of 51,2 % (representing an incidence of 1 case per 758 inhabitants per year in the elderly population of our region) and an in-hospital mortality rate of 15,6 % (19,1 % if transferred patients are excluded) among older adults with PCR-confirmed RSV infection. Heart failure (p ≤ 0.001), asthma (p = 0005), chronic kidney disease (p = 0006), chronic obstructive pulmonary disease (p = 0,02) and active smoking (p = 0.01) were risk factors for hospitalization. Older age (p = 0.003), residing in long-term care facility (p = 0.003), active cancer (p = 0,01), lower lymphocytes (p ≤ 0,001) and higher creatinine (p = 0,01) were significantly associated with mortality.

Conclusions

This is the first review of health outcomes related to RSV infection in the elderly from a Portuguese hospital. It identifies a high burden of hospitalization and in-hospital mortality in the elderly population. Our findings highlight the need for increased awareness of RSV infection in adults, particularly older adults, and underscore the importance of targeted interventions, such as vaccination programs, to reduce the burden of this disease in vulnerable populations in Portugal.

成人呼吸道合胞病毒（RSV）感染的研究尚不充分。越来越多的检测正在揭示最普遍的下呼吸道感染中出现严重后果的新情况。了解危险因素变得越来越重要，特别是考虑到最近批准预防性疫苗接种。方法回顾性评价我院从2021年至2024年连续三个感染季节检测到的所有实时聚合酶链反应阳性的60岁及以上成人RSV病例。对需要住院治疗的严重感染患者的后续评估。结果共纳入574例，其中女性占57%，中位年龄81.1岁（IQR 74 ~ 87岁）。病例高峰发生在9月至3月。我们发现，在pcr确诊的RSV感染的老年人中，住院率为51.2%（代表我们地区老年人口每年每758名居民中有1例的发病率），住院死亡率为15.6%（如果排除转院患者，则为19.1%）。心衰（p≤0.001）、哮喘（p = 0005）、慢性肾脏疾病（p = 0006）、慢性阻塞性肺疾病（p = 0.02）和主动吸烟（p = 0.01）是住院的危险因素。年龄较大（p = 0.003）、居住在长期护理机构（p = 0.003）、活动性癌症（p = 0.01）、淋巴细胞降低（p≤0.001）和肌酐升高（p = 0.01）与死亡率显著相关。结论：这是对葡萄牙医院老年人RSV感染相关健康结果的首次回顾。它确定了老年人口住院和住院死亡率的高负担。我们的研究结果强调需要提高成年人，特别是老年人对呼吸道合胞病毒感染的认识，并强调有针对性的干预措施的重要性，例如疫苗接种计划，以减轻葡萄牙脆弱人群对这种疾病的负担。

{"title":"Severe respiratory syncytial virus infection in older adults – burden, clinical outcomes and implications for care","authors":"Daniel Guimarães de Oliveira , Ana Grande , Francisco Belchior , Rafaela Costa , Rita Francisco , Natália Oliveira , Maria Calle","doi":"10.1016/j.resmer.2025.101173","DOIUrl":"10.1016/j.resmer.2025.101173","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) infection in adults remains under-researched. Increased testing is revealing an emerging picture of severe outcomes within the most prevalent lower respiratory tract infections. Understanding risk factors is increasingly important, especially in light of the recent approval of prophylactic vaccination.</div></div><div><h3>Methods</h3><div>Retrospective evaluation of all real-time polymerase chain reaction-positive RSV cases detected at our institution over three consecutive infection seasons from 2021 to 2024 in adults aged 60 years and older. Subsequent assessment of patients with severe infection requiring hospitalization.</div></div><div><h3>Results</h3><div>A total of 574 individuals were included, 57 % of whom were female, with a median age of 81,1 years (IQR 74–87 years). The peak number of cases occurred between September and March. We found a hospitalization rate of 51,2 % (representing an incidence of 1 case per 758 inhabitants per year in the elderly population of our region) and an in-hospital mortality rate of 15,6 % (19,1 % if transferred patients are excluded) among older adults with PCR-confirmed RSV infection. Heart failure (<em>p</em> ≤ 0.001), asthma (<em>p</em> = 0005), chronic kidney disease (<em>p</em> = 0006), chronic obstructive pulmonary disease (<em>p</em> = 0,02) and active smoking (<em>p</em> = 0.01) were risk factors for hospitalization. Older age (<em>p</em> = 0.003), residing in long-term care facility (<em>p</em> = 0.003), active cancer (<em>p</em> = 0,01), lower lymphocytes (<em>p</em> ≤ 0,001) and higher creatinine (<em>p</em> = 0,01) were significantly associated with mortality.</div></div><div><h3>Conclusions</h3><div>This is the first review of health outcomes related to RSV infection in the elderly from a Portuguese hospital. It identifies a high burden of hospitalization and in-hospital mortality in the elderly population. Our findings highlight the need for increased awareness of RSV infection in adults, particularly older adults, and underscore the importance of targeted interventions, such as vaccination programs, to reduce the burden of this disease in vulnerable populations in Portugal.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101173"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020 肺癌患者吸食大麻的结果：来自KBP-CPHG-2020的研究结果

IF 2.2 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-05-08 DOI: 10.1016/j.resmer.2025.101174

Sébastien Couraud , Olivier Molinier , Marielle Sabatini , Séverine Thomassin , Rym Haouachi , Virginie Levrat , Hannah Ghalloussi-Tebai , Antoine Belle , Laurent Mosser , Sébastien Larive , Alexandra Bedossa , Alexia Letierce , Hugues Morel , Didier Debieuvre , Study Group KBP-2020-CPHG

Introduction

Cannabis smoking is suspected to be a risk factor for lung cancer. The KBP-2020-CPHG study is a prospective study that collected data from all patients with newly diagnosed lung cancer in non-academic hospitals in France in 2020.

Method

We conducted comparative and matched cohort analyses using the dataset, in which cannabis smokers (i.e. participants who self-declared a lifetime intake of ≥20 joints) were compared with tobacco-only smokers. After matching on confounders, we compared age at diagnosis and overall survival.

Results

Among 8999 patients, 314 (3.6%) were cannabis smokers and 7372 were tobacco-only smokers (data missing for 183). Cannabis smokers were younger than tobacco-only smokers at lung cancer diagnosis (mean [± standard deviation] 52.9 [±8.84] versus 67.7 [±9.51] years; p<0.0001), and this difference remained in the paired analysis (matched for histology, sex and cigarette pack-years [±5 pack-years]; n = 298 pairs; median age at diagnosis 53.1 vs 64.8 years; hazard ratio 5.61, 95% CI 4.10–7.68; p<0.0001). Histological type was also different between the two groups, with more cases of adenocarcinoma and large cell neuroendocrine carcinoma among cannabis smokers. Finally, a 1:1 matched analysis controlled for age, sex, stage, histology and cigarette pack-years showed that overall survival was not affected by cannabis smoking (HR 0.90, 95% CI 0.68–1.18; p = 0.44).

Conclusion

We provide a detailed description of lung cancer characteristics among cannabis smokers compared with tobacco-only smokers. Cannabis smoking appeared to be associated with lung cancer diagnosis at an earlier age and was not a prognostic factor for mortality.

吸食大麻被怀疑是肺癌的一个危险因素。KBP-2020-CPHG研究是一项前瞻性研究，收集了2020年法国非学术医院所有新诊断肺癌患者的数据。方法我们使用数据集进行了比较和匹配队列分析，其中大麻吸烟者（即自称终身吸烟≥20支的参与者）与仅吸烟的吸烟者进行了比较。在对混杂因素进行匹配后，我们比较了诊断时的年龄和总生存率。结果8999例患者中，314例（3.6%）为大麻吸烟者，7372例为纯烟草吸烟者（183例数据缺失）。在肺癌诊断时，吸食大麻者比只吸食烟草者年轻(平均[±标准差]52.9[±8.84]比67.7[±9.51]岁；P<0.0001)，这一差异在配对分析中仍然存在(匹配组织学、性别和卷烟包年[±5包年]；N = 298对；诊断时中位年龄53.1 vs 64.8岁；风险比5.61,95% CI 4.10-7.68；术中,0.0001)。两组之间的组织学类型也不同，吸食大麻者中腺癌和大细胞神经内分泌癌的病例较多。最后，一项控制年龄、性别、分期、组织学和卷烟包年的1:1匹配分析显示，吸食大麻不影响总体生存(HR 0.90, 95% CI 0.68-1.18；P = 0.44)。结论：我们提供了大麻吸烟者与纯烟草吸烟者肺癌特征的详细描述。吸食大麻似乎与早期肺癌诊断有关，而不是死亡率的预后因素。

{"title":"Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020","authors":"Sébastien Couraud , Olivier Molinier , Marielle Sabatini , Séverine Thomassin , Rym Haouachi , Virginie Levrat , Hannah Ghalloussi-Tebai , Antoine Belle , Laurent Mosser , Sébastien Larive , Alexandra Bedossa , Alexia Letierce , Hugues Morel , Didier Debieuvre , Study Group KBP-2020-CPHG","doi":"10.1016/j.resmer.2025.101174","DOIUrl":"10.1016/j.resmer.2025.101174","url":null,"abstract":"<div><h3>Introduction</h3><div>Cannabis smoking is suspected to be a risk factor for lung cancer. The KBP-2020-CPHG study is a prospective study that collected data from all patients with newly diagnosed lung cancer in non-academic hospitals in France in 2020.</div></div><div><h3>Method</h3><div>We conducted comparative and matched cohort analyses using the dataset, in which cannabis smokers (i.e. participants who self-declared a lifetime intake of ≥20 joints) were compared with tobacco-only smokers. After matching on confounders, we compared age at diagnosis and overall survival.</div></div><div><h3>Results</h3><div>Among 8999 patients, 314 (3.6%) were cannabis smokers and 7372 were tobacco-only smokers (data missing for 183). Cannabis smokers were younger than tobacco-only smokers at lung cancer diagnosis (mean [± standard deviation] 52.9 [±8.84] <em>versus</em> 67.7 [±9.51] years; p<0.0001), and this difference remained in the paired analysis (matched for histology, sex and cigarette pack-years [±5 pack-years]; n = 298 pairs; median age at diagnosis 53.1 <em>vs</em> 64.8 years; hazard ratio 5.61, 95% CI 4.10–7.68; p<0.0001). Histological type was also different between the two groups, with more cases of adenocarcinoma and large cell neuroendocrine carcinoma among cannabis smokers. Finally, a 1:1 matched analysis controlled for age, sex, stage, histology and cigarette pack-years showed that overall survival was not affected by cannabis smoking (HR 0.90, 95% CI 0.68–1.18; p = 0.44).</div></div><div><h3>Conclusion</h3><div>We provide a detailed description of lung cancer characteristics among cannabis smokers compared with tobacco-only smokers. Cannabis smoking appeared to be associated with lung cancer diagnosis at an earlier age and was not a prognostic factor for mortality.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101174"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of interstitial lung diseases in a native Afro-Caribbean population of French West Indies 法属西印度群岛土著非裔加勒比人间质性肺病流行病学研究

IF 2.2 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-05-08 DOI: 10.1016/j.resmer.2025.101175

Sylvain Neveu , Milène Chaptal , Elodie Rossigneux , Hilario Nunes , Chantal Raherison-Semjen

Introduction

Data about interstitial lung diseases (ILDs) epidemiology in the Afro-Caribbean population is lacking. Differences in incidence and prevalence compared to European populations have already been reported. The main objective of this study was to estimate ILD incidence in Guadeloupe overall and by etiology. The secondary objective was to determine the clinical, demographic, and environmental characteristics of patients with ILD.

Materials and methods

We conducted a descriptive epidemiological study to estimate the incidence and prevalence of ILD in Guadeloupe between 2013 and 2019 and assess its etiological distribution.

Results

A total of 235 ILD cases in Guadeloupe were included. The incidence of ILD was 6.87 cases per 100,000 population per year, and the prevalence was 32.22 cases per 100,000 population. ILDs associated with connective tissue diseases accounted for 34 % of cases, with an incidence of 2.12 per 100,000 population. Sarcoidosis represented 31 % of cases, with an incidence of 1.72 per 100,000 population. Idiopathic ILDs made up 21 % of cases, with an incidence of 1.72 per 100,000 population. In this cohort, 25 % of patients were smokers, and 29 % of those with idiopathic pulmonary fibrosis (IPF) were farmers or agricultural workers.

Conclusion

We report the first study on ILD epidemiology in a native Afro-Caribbean population. Incidence and prevalence figures are lower than those previously reported in European populations. The main etiologies were connective tissue diseases, sarcoidosis, and idiopathic ILD.

关于非裔加勒比人口间质性肺病（ILDs）流行病学的数据缺乏。与欧洲人群相比，发病率和流行率的差异已经有报道。本研究的主要目的是估计瓜德罗普岛ILD的总体发病率和病因。次要目的是确定ILD患者的临床、人口学和环境特征。材料和方法我们进行了一项描述性流行病学研究，估计2013年至2019年瓜德罗普岛ILD的发病率和患病率，并评估其病因分布。结果在瓜德罗普岛共纳入235例ILD病例。每年ILD的发病率为6.87例/ 10万人，患病率为32.22例/ 10万人。与结缔组织疾病相关的ild占病例的34%，发病率为每10万人2.12例。结节病占31%的病例，发病率为每10万人1.72例。特发性ild占21%，发病率为每10万人1.72例。在这个队列中，25%的患者是吸烟者，29%的特发性肺纤维化（IPF）患者是农民或农业工人。结论本研究首次报道了加勒比非洲土著人群的ILD流行病学研究。发病率和流行率低于以前报道的欧洲人群。主要病因为结缔组织病、结节病和特发性ILD。

{"title":"Epidemiology of interstitial lung diseases in a native Afro-Caribbean population of French West Indies","authors":"Sylvain Neveu , Milène Chaptal , Elodie Rossigneux , Hilario Nunes , Chantal Raherison-Semjen","doi":"10.1016/j.resmer.2025.101175","DOIUrl":"10.1016/j.resmer.2025.101175","url":null,"abstract":"<div><h3>Introduction</h3><div>Data about interstitial lung diseases (ILDs) epidemiology in the Afro-Caribbean population is lacking. Differences in incidence and prevalence compared to European populations have already been reported. The main objective of this study was to estimate ILD incidence in Guadeloupe overall and by etiology. The secondary objective was to determine the clinical, demographic, and environmental characteristics of patients with ILD.</div></div><div><h3>Materials and methods</h3><div>We conducted a descriptive epidemiological study to estimate the incidence and prevalence of ILD in Guadeloupe between 2013 and 2019 and assess its etiological distribution.</div></div><div><h3>Results</h3><div>A total of 235 ILD cases in Guadeloupe were included. The incidence of ILD was 6.87 cases per 100,000 population per year, and the prevalence was 32.22 cases per 100,000 population. ILDs associated with connective tissue diseases accounted for 34 % of cases, with an incidence of 2.12 per 100,000 population. Sarcoidosis represented 31 % of cases, with an incidence of 1.72 per 100,000 population. Idiopathic ILDs made up 21 % of cases, with an incidence of 1.72 per 100,000 population. In this cohort, 25 % of patients were smokers, and 29 % of those with idiopathic pulmonary fibrosis (IPF) were farmers or agricultural workers.</div></div><div><h3>Conclusion</h3><div>We report the first study on ILD epidemiology in a native Afro-Caribbean population. Incidence and prevalence figures are lower than those previously reported in European populations. The main etiologies were connective tissue diseases, sarcoidosis, and idiopathic ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101175"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding participation challenges in lung cancer screening program: Findings from the DEP’KP80 trial in France 了解参与肺癌筛查项目的挑战：来自法国DEP 'KP80试验的发现

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-09-17 DOI: 10.1016/j.resmer.2025.101208

Sébastien Couraud , Emmanuel Grolleau , Bernard Milleron , Valérie Petigny , Olivier Leleu

Background

Lung cancer is the leading cause of cancer-related mortality worldwide. Low-dose computed tomography (LDCT) screening can significantly reduce mortality among high-risk populations. However, participation rates in lung cancer screening programs are often suboptimal due to various barriers.

Method

The DEP’KP80 trial is a multicentric prospective study conducted in the French territory of Somme, assessing the feasibility of lung cancer screening using LDCT. Participants aged 55–74 with a smoking history of over 30 pack-years were recruited between 2016 and 2020. A questionnaire was administered to all participants to evaluate motivations and barriers to participation.

Results

The trial enrolled 1369 participants, with 30.4 % responding to the questionnaire. Of the responders, 65 % were male, and the mean age was 61.9 years. Key motivations for participation included health concerns related to smoking (68.7 %) and healthcare professional advice (16.5 %). Main barriers were perceived lack of invitation (37.5 %) and logistical issues (21.9 %). Notably, 63 % of responders reported that participation led to smoking cessation. In addition, the most common source of information about the program was healthcare professionals (85 %).

Conclusion

Our study highlights the crucial role of healthcare professionals in promoting lung cancer screening and identifies significant barriers to participation. Addressing these barriers through targeted interventions could enhance screening uptake and improve lung cancer outcomes.

背景肺癌是全球癌症相关死亡的主要原因。低剂量计算机断层扫描（LDCT）筛查可显著降低高危人群的死亡率。然而，由于各种障碍，肺癌筛查项目的参与率往往不是最佳的。DEP’kp80试验是一项在法国索姆省开展的多中心前瞻性研究，旨在评估LDCT筛查肺癌的可行性。参与者年龄在55-74岁之间，吸烟史超过30包年，于2016年至2020年间招募。对所有参与者进行了问卷调查，以评估参与的动机和障碍。结果共纳入1369名受试者，30.4 %的受试者回答了问卷调查。在应答者中，65% %为男性，平均年龄为61.9岁。参与的主要动机包括与吸烟有关的健康问题（68.7% %）和保健专业咨询（16.5% %）。主要障碍是缺乏邀请（37.5% %）和后勤问题（21.9% %）。值得注意的是，63% %的应答者报告说参与导致了戒烟。此外，关于该计划的最常见信息来源是医疗保健专业人员（85% %）。结论我们的研究强调了医疗保健专业人员在促进肺癌筛查方面的关键作用，并确定了参与筛查的重大障碍。通过有针对性的干预措施解决这些障碍，可以提高筛查的接受程度，改善肺癌的预后。

{"title":"Understanding participation challenges in lung cancer screening program: Findings from the DEP’KP80 trial in France","authors":"Sébastien Couraud , Emmanuel Grolleau , Bernard Milleron , Valérie Petigny , Olivier Leleu","doi":"10.1016/j.resmer.2025.101208","DOIUrl":"10.1016/j.resmer.2025.101208","url":null,"abstract":"<div><h3>Background</h3><div>Lung cancer is the leading cause of cancer-related mortality worldwide. Low-dose computed tomography (LDCT) screening can significantly reduce mortality among high-risk populations. However, participation rates in lung cancer screening programs are often suboptimal due to various barriers.</div></div><div><h3>Method</h3><div>The DEP’KP80 trial is a multicentric prospective study conducted in the French territory of Somme, assessing the feasibility of lung cancer screening using LDCT. Participants aged 55–74 with a smoking history of over 30 pack-years were recruited between 2016 and 2020. A questionnaire was administered to all participants to evaluate motivations and barriers to participation.</div></div><div><h3>Results</h3><div>The trial enrolled 1369 participants, with 30.4 % responding to the questionnaire. Of the responders, 65 % were male, and the mean age was 61.9 years. Key motivations for participation included health concerns related to smoking (68.7 %) and healthcare professional advice (16.5 %). Main barriers were perceived lack of invitation (37.5 %) and logistical issues (21.9 %). Notably, 63 % of responders reported that participation led to smoking cessation. In addition, the most common source of information about the program was healthcare professionals (85 %).</div></div><div><h3>Conclusion</h3><div>Our study highlights the crucial role of healthcare professionals in promoting lung cancer screening and identifies significant barriers to participation. Addressing these barriers through targeted interventions could enhance screening uptake and improve lung cancer outcomes.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101208"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The predicted value of maximal inspiratory pressure, maximal expiratory pressure, and sniff nasal inspiratory pressure for southeast asian adults 东南亚成人最大吸气压力、最大呼气压力和嗅鼻吸气压力的预测值

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-09-30 DOI: 10.1016/j.resmer.2025.101212

Ngoc-Minh Nguyen , Hanh Thi-Bich Tran , Thi-Quynh-Nhu Do , Nicolas Audag , Giuseppe Liistro , Philippe Fait , Gregory Reychler

Background

Accurate assessment of respiratory muscle strength is crucial for diagnosing and managing respiratory diseases. However, existing reference values may not be generalizable across diverse populations. This study aimed to establish predicted values for maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and sniff nasal inspiratory pressure (SNIP) in Southeast Asian adults.

Methods

MIP, MEP, and SNIP were measured in 301 healthy Vietnamese adults. Two-way ANOVA and post-hoc tests were used to examine differences in these measures among age groups and between genders. Stepwise multiple linear regression was used to develop predictive equations for MIP, MEP, and SNIP, with potential predictors including age, gender, body mass index, and lung function. The lower limit of the normal range (LLN) was determined using the fifth percentile of the negative residuals.

Results

MIP, MEP, and SNIP were higher in males than in females. MIP and MEP declined with age, while SNIP remained relatively stable. Predictive equations were established: MIP = 95.2 – 32.1 x gender (male = 0, female = 1) – 0.41 x age + 1.2 x BMI (adjusted R²: 41 %, LLN = predicted MIP – 34), MEP = 135.1 – 46.75 x gender (male = 0, female = 1) - 0.6 x age + 1.34 x BMI (adjusted R²: 41.8 %, LLN = predicted MEP – 50), SNIP = 63.8 – 18.16 x gender (male = 0, female = 1) (adjusted R²: 14.8 %, LLN = predicted SNIP – 30).

Conclusions

This study provides ethnic-specific predictive equations for MIP, MEP, and SNIP, which may serve as a preliminary step toward developing reference values for the Southeast Asian region.

背景：准确评估呼吸肌力量对诊断和治疗呼吸系统疾病至关重要。然而，现有的参考值可能无法在不同的人群中推广。本研究旨在建立东南亚成年人最大吸气压力（MIP）、最大呼气压力（MEP）和嗅鼻吸气压力（SNIP）的预测值。方法测定301例越南健康成人的smip、MEP和SNIP。采用双向方差分析和事后检验来检验这些措施在年龄组和性别之间的差异。采用逐步多元线性回归建立MIP、MEP和SNIP的预测方程，潜在的预测因子包括年龄、性别、体重指数和肺功能。正常范围的下限（LLN）是用负残差的第5个百分位数确定的。结果男性smip、MEP、SNIP均高于女性。MIP和MEP随年龄增长而下降，而SNIP保持相对稳定。建立了预测方程:MIP = 95.2 - 32.1 x性别(男= 0,女= 1)- 0.41 x + 1.2岁BMI (R2调整:41%,LLN =预测MIP - 34),欧洲议会议员= 135.1 - 46.75 x性别(男= 0,女= 1)- 0.6 x + 1.34岁BMI (R2调整:41.8%,LLN =预测MEP - 50),剪断= 63.8 - 18.16 x性别(男= 0,女= 1)(R2调整:14.8%,LLN =预测剪断- 30)。结论本研究提供了种族特异性的MIP、MEP和SNIP预测方程，为东南亚地区开发参考值奠定了基础。

{"title":"The predicted value of maximal inspiratory pressure, maximal expiratory pressure, and sniff nasal inspiratory pressure for southeast asian adults","authors":"Ngoc-Minh Nguyen , Hanh Thi-Bich Tran , Thi-Quynh-Nhu Do , Nicolas Audag , Giuseppe Liistro , Philippe Fait , Gregory Reychler","doi":"10.1016/j.resmer.2025.101212","DOIUrl":"10.1016/j.resmer.2025.101212","url":null,"abstract":"<div><h3>Background</h3><div>Accurate assessment of respiratory muscle strength is crucial for diagnosing and managing respiratory diseases. However, existing reference values may not be generalizable across diverse populations. This study aimed to establish predicted values for maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and sniff nasal inspiratory pressure (SNIP) in Southeast Asian adults.</div></div><div><h3>Methods</h3><div>MIP, MEP, and SNIP were measured in 301 healthy Vietnamese adults. Two-way ANOVA and post-hoc tests were used to examine differences in these measures among age groups and between genders. Stepwise multiple linear regression was used to develop predictive equations for MIP, MEP, and SNIP, with potential predictors including age, gender, body mass index, and lung function. The lower limit of the normal range (LLN) was determined using the fifth percentile of the negative residuals.</div></div><div><h3>Results</h3><div>MIP, MEP, and SNIP were higher in males than in females. MIP and MEP declined with age, while SNIP remained relatively stable. Predictive equations were established: MIP = 95.2 – 32.1 x gender (male = 0, female = 1) – 0.41 x age + 1.2 x BMI (adjusted <em>R<sup>2</sup></em>: 41 %, LLN = predicted MIP – 34), MEP = 135.1 – 46.75 x gender (male = 0, female = 1) - 0.6 x age + 1.34 x BMI (adjusted <em>R<sup>2</sup></em>: 41.8 %, LLN = predicted MEP – 50), SNIP = 63.8 – 18.16 x gender (male = 0, female = 1) (adjusted <em>R<sup>2</sup></em>: 14.8 %, LLN = predicted SNIP – 30).</div></div><div><h3>Conclusions</h3><div>This study provides ethnic-specific predictive equations for MIP, MEP, and SNIP, which may serve as a preliminary step toward developing reference values for the Southeast Asian region.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101212"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “Particle size distribution of viable nebulized bacteriophage for the treatment of multi-drug resistant Pseudomonas aeruginosa” [Respiratory Medicine and Research 86 (2024) 101133] “治疗多重耐药铜绿假单胞菌的活菌雾化噬菌体粒径分布”[呼吸医学与研究86(2024)101133]的勘误。

IF 1.8 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-10-08 DOI: 10.1016/j.resmer.2025.101209

Daniel L Thompson , Zoe Semersky , Richard Feinn , Pamela Huang , Paul E Turner , Ben K Chan , Jonathan L Koff , Thomas S Murray

引用次数: 0

Emerging respiratory challenges in space and long-duration missions 太空和长时间任务中新出现的呼吸挑战

IF 2.2 4区医学 Q3 RESPIRATORY SYSTEM

Respiratory Medicine and Research

Pub Date : 2025-11-01 Epub Date: 2025-07-01 DOI: 10.1016/j.resmer.2025.101188

Benjamin Pequignot , Seamus Thierry , G Kim Prisk , Mickael Lescroart

引用次数: 0